Brainstorm Cell Therapeutics Inc (BCLI) Quote

BrainStorm Announces New Survival Data from Expanded Access Program Cohort: Remarkably 90% of ALS Patients Survived Over 5 Years with NurOwn®

https://seekingalpha.com/pr/20137408-brainstorm-announces-new-survival-data-from-expanded-access-program-cohort-remarkably-90

Look for a short position soon enough 

1.53 News good but offering cash short in future might let it run a little to trap longs.. NurOwn® data selected as Breakthrough Science for Presentation at ISCT 2025 MeetingThe new pharmacogenomic were delivered in a oral presentation at the International Society for Cell & Gene Therapy (ISCT) 2025 Annual Meeting, in New Orleans. The data highlight the impact of the UNC13A genotype on clinical outcomes for ALS patients treated with NurOwn. The presentation was featured in the ISCT public announcement regarding the meeting, which indicated that the data were "carefully reviewed and selected by the ISCT 2025 Planning Faculty, to explore the latest breakthroughs in the clinical translation of Mesenchymal Stem/Stromal Cells and how they will shape the future of cell therapies."...

BCLI.........................................................p/m

Looking good $2

AHA! Because!

but why?

$BCLI Moving up nicely!

BCLI Time for an impressive update/news and rise!

$BCLI Adding/added! $BCLI has submitted an IND amendment to the #FDA to support the initiation of a Phase 3b clinical trial evaluating NurOwn® in ALS. This important regulatory milestone reflects our continued commitment to the ALS community and advancing potential treatment options through rigorous… pic.twitter.com/KEvJIp5TfI— BrainStorm (@BrainstormCell) April 10, 2025

$BCLI $BCLI Nasdaq. Added!
BrainStorm Cell Therapeutics Submits IND Amendment to FDA, Paving the Way for Phase 3b Trial of NurOwn® in ALS
https://www.otcmarkets.com/stock/BCLI/news/story?e&id=3205525

BCLI under $2

BCLI under $3

BCLI, new 52/low

BCLI 1.30 + 10% Israeli company low floater decent news.. NEW YORK, Nov. 11, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced that it has entered into a Memorandum of Understanding (MOU) with Pluri Inc. (NASDAQ: PLUR) through its wholly owned subsidiary ("Pluri"), an established global leader in the development and manufacturing of cell-based therapeutics, to manufacture NurOwn® for use in BrainStorm's planned Phase 3b trial in amyotrophic lateral sclerosis (ALS). This MOU enables BrainStorm to begin transfer of its manufacturing technology and start producing NurOwn at Pluri's manufacturing facility upon finalizing the binding definitive agreement.

BCLI, new 52 week low

BCLI under $3

BrainStorm Cell Therapeutics Announces Peer-reviewed Publication of Biomarker Data from NurOwn's® Phase 3 Clinical Trial in ALS

Up 12.14% today and another 26.0274% in after hours training. Something's happening. Maybe someone leaked positive info about the Phase 3b trial.

Great day today! Up 31.03%. Hope to see a lot more of this.

what going on today? no news show on Fidelity.

Top line results on 29th,still very little buying,lots of darkpool that looked like buying today and aftermarket,watching closely for actual buying with accumulation

chased and got killed here.. my fault.. too impulsive.

Our team is diligently preparing to submit a clinical protocol, and Statistical Analysis Plan, for the FDA's review. Following alignment with the FDA's expectations, we will formally submit our SPA request. We anticipate making this submission in February 2024. The FDA's response is expected within 45 days of submission.
The process is long, i do not forsee results before mid 2025 earliest.
Myself i am long ago out, and only following the company for academic reasons.

Hopefully, they will set higher ALSFRS-R scores in the new study for the trial subjects so there will not be a floor effect again. Also, in a perfect world where everything goes our way, how long do you think this new study will take before we see the results?

Dear Shareholders,

We remain steadfast in our commitment to advancing NurOwn as a promising treatment for ALS patients. Recognizing the challenges faced in our recent BLA submission, we are ambitiously pursuing a Phase 3b trial, aligning with our dedication to the ALS community and our goal of making NurOwn commercially available. Despite the setbacks with the ADCOM's unfavorable vote, our focus remains to align with the FDA on a phase 3b trial design, as we acknowledge that this represents the most expedient pathway to approval.

We are exploring various strategies to secure the necessary funding. We intend to seek a Special Protocol Assessment (SPA), which, when agreed with the FDA, could significantly de-risk the regulatory aspects of the NurOwn program. We are very encouraged by the FDA's ongoing engagement, including the opportunity provided by the expedited in-person Type A meeting on December 6, a rare occurrence in today's regulatory environment. We appreciate the Agency's feedback, comments and other regulatory accommodations, signaling its recognition for the unmet need in ALS and its willingness to reach alignment with Brainstorm on our new clinical strategy.

Our team is diligently preparing to submit a clinical protocol, and Statistical Analysis Plan, for the FDA's review. Following alignment with the FDA's expectations, we will formally submit our SPA request. We anticipate making this submission in February 2024. The FDA's response is expected within 45 days of submission.

We believe that agreement on an SPA would open a broad spectrum of financing options for the trial. Concurrently, we are committed to maintaining our NASDAQ listing status. Our strategy focuses on enhancing the value of our assets, thereby garnering market support that is crucial for our stock price to reach its requisite level by April. We prefer this approach over a reverse stock split, as it aligns more closely with our long-term goals and shareholder interests.

We thank you for your continued support. Your faith in our mission fuels our determination to overcome the recent challenges and ultimately deliver groundbreaking treatments that will help patients in need and create value for our stakeholders.

Sincerely,

Chaim Lebovits
President and CEO
BrainStorm Cell Therapeutics Inc

BRAINSTORM CELL THERAPEUTICS INC.
Annual Meeting of Stockholders

https://east.virtualshareholdermeeting.com/vsm/web?pvskey=BCLI2023AM

BRAINSTORM CELL THERAPEUTICS INC. is hosting a Virtual Stockholder Meeting on Monday, December 18, 2023 at 10:00 AM, Eastern Time, and the stockholders of record will be able to vote and ask questions online during the meeting. If you would like to attend the virtual meeting and have your control number, please log in 15 minutes prior to the start of the meeting.

To the Stockholders of Brainstorm Cell Therapeutics Inc.:
Notice is hereby given that the December 2023 Annual Meeting of Stockholders (the “Meeting”) of
Brainstorm Cell Therapeutics Inc. (the “Company”) will be held on December 18, 2023 at 10:00 a.m.,
Eastern time, virtually via the internet at central.virtualshareholderm..., for the
following purposes

BRAINSTORM CELL THERAPEUTICS INC.'s Virtual Shareholder's Meeting - Pre meeting message page
https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=317853002&type=PDF&symbol=BCLI&cdn=149521fc0e34b68e67d975b2a1a58943&companyName=Brainstorm+Cell+Therapeutics+Inc.&formType=DEF+14A&dateFiled=2023-11-08

3,773,000 shares short!!! Time to cover?

Law firms short,posting ads like crazy before big day,being sued for poorly written disclosure warnings on prs,pffft

Patience,death hour over in 10min

Saying “E-X-C-E-L-L-E-N-T”in my best mad scientist voice,while drumming my fingers together.31s filled,now bidding .30s and .28s (doesn’t look like those will fill,bounced off the dma50 on 10min,also the previous run ceiling.29 on the 30th)

Some selling expected first 30min,ppl out of day trades yesterday profit taking today or thinking they can flip

Tomorrow is the big day,Christmas is tomorrow

BCLI ON THE MOVE

#BCLI 🔥 50% gain opportunity for gap up! See chart! $BCLI

Sold

Dec 6th FDA meeting coming quick here... Loaded up here...

Load them up boys... Dec 6th FDA meeting..$BCLI

BCLI, Big catalyst coming: it will have a meeting with FDA on Dec 6 for its Phase 3 trial. It was $3.2 in June.

Load

Getting noticed more I’d grab some or miss out

Dec 6 meeting with the FDA. Thinking the deck is stacked against this making it to market without a more robust clinical trial.

Still, looked like this could see a short pop.

Thanks brother

Shares available to short dropped 50% today,could see ZERO BORROW soon and huge run usually follows,I am in,just waiting now,chart looks great and lots of run room,potential is good,risk is low. Good skill to you!!

Hope so been adding to make the chart look good

4M+ short,squeeze could be huge

Still rising

Still collapsing shorts getting paid $$

Good News: $BCLI Published US Patent App #20230310507 Today For "METHODS AND COMPOSITIONS FOR TREATING LUNG CONDITIONS
https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/20230310507